Your browser doesn't support javascript.
loading
Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.
Ramis-Zaldivar, Joan Enric; Gonzalez-Farré, Blanca; Balagué, Olga; Celis, Verónica; Nadeu, Ferran; Salmerón-Villalobos, Julia; Andrés, Mara; Martin-Guerrero, Idoia; Garrido-Pontnou, Marta; Gaafar, Ayman; Suñol, Mariona; Bárcena, Carmen; Garcia-Bragado, Federico; Andión, Maitane; Azorín, Daniel; Astigarraga, Itziar; Sagaseta de Ilurdoz, Maria; Sábado, Constantino; Gallego, Soledad; Verdú-Amorós, Jaime; Fernandez-Delgado, Rafael; Perez, Vanesa; Tapia, Gustavo; Mozos, Anna; Torrent, Montserrat; Solano-Páez, Palma; Rivas-Delgado, Alfredo; Dlouhy, Ivan; Clot, Guillem; Enjuanes, Anna; López-Guillermo, Armando; Galera, Pallavi; Oberley, Matthew J; Maguire, Alanna; Ramsower, Colleen; Rimsza, Lisa M; Quintanilla-Martinez, Leticia; Jaffe, Elaine S; Campo, Elías; Salaverria, Itziar.
Afiliação
  • Ramis-Zaldivar JE; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Gonzalez-Farré B; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
  • Balagué O; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Celis V; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
  • Nadeu F; Hematopathology Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Salmerón-Villalobos J; Hematopathology Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Andrés M; Pediatric Oncology Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain.
  • Martin-Guerrero I; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Garrido-Pontnou M; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
  • Gaafar A; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Suñol M; Pediatric Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, Valencia, Spain.
  • Bárcena C; Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, University of the Basque Country, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, Leioa, Spain.
  • Garcia-Bragado F; Pediatric Oncology Unit, Hospital Universitario Cruces Osakidetza, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
  • Andión M; Pathology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Azorín D; Pathology Department, Hospital Universitario Cruces Osakidetza, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
  • Astigarraga I; Pathology Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain.
  • Sagaseta de Ilurdoz M; Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Sábado C; Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Gallego S; Pediatric Oncology Department and.
  • Verdú-Amorós J; Pathology Department, Hospital Universitario Infantil Niño Jesus, Madrid, Spain.
  • Fernandez-Delgado R; Pediatric Oncology Unit, Hospital Universitario Cruces Osakidetza, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
  • Perez V; Pediatric Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Tapia G; Pediatric Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Mozos A; Pediatric Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Torrent M; Pediatric Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Solano-Páez P; Pediatric Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Rivas-Delgado A; Pediatric Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Dlouhy I; Pathology Department, Hospital Trias i Pujol, Badalona, Spain.
  • Clot G; Pathology Department and.
  • Enjuanes A; Pediatric Oncology Department, Hospital de Sant Pau i la Santa Creu, Barcelona, Spain.
  • López-Guillermo A; Pediatric Oncology Department, Hospital Virgen del Rocio, Sevilla, Spain.
  • Galera P; Hematopathology Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Oberley MJ; Hematopathology Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Maguire A; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Ramsower C; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
  • Rimsza LM; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Quintanilla-Martinez L; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
  • Jaffe ES; Hematopathology Unit, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
  • Campo E; Laboratory of Pathology, National Institutes of Health, Bethesda, MD.
  • Salaverria I; Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA.
Blood ; 135(4): 274-286, 2020 01 23.
Article em En | MEDLINE | ID: mdl-31738823
ABSTRACT
Pediatric large B-cell lymphomas (LBCLs) share morphological and phenotypic features with adult types but have better prognosis. The higher frequency of some subtypes such as LBCL with IRF4 rearrangement (LBCL-IRF4) in children suggests that some age-related biological differences may exist. To characterize the genetic and molecular heterogeneity of these tumors, we studied 31 diffuse LBCLs (DLBCLs), not otherwise specified (NOS); 20 LBCL-IRF4 cases; and 12 cases of high-grade B-cell lymphoma (HGBCL), NOS in patients ≤25 years using an integrated approach, including targeted gene sequencing, copy-number arrays, and gene expression profiling. Each subgroup displayed different molecular profiles. LBCL-IRF4 had frequent mutations in IRF4 and NF-κB pathway genes (CARD11, CD79B, and MYD88), losses of 17p13 and gains of chromosome 7, 11q12.3-q25, whereas DLBCL, NOS was predominantly of germinal center B-cell (GCB) subtype and carried gene mutations similar to the adult counterpart (eg, SOCS1 and KMT2D), gains of 2p16/REL, and losses of 19p13/CD70. A subset of HGBCL, NOS displayed recurrent alterations of Burkitt lymphoma-related genes such as MYC, ID3, and DDX3X and homozygous deletions of 9p21/CDKN2A, whereas other cases were genetically closer to GCB DLBCL. Factors related to unfavorable outcome were age >18 years; activated B-cell (ABC) DLBCL profile, HGBCL, NOS, high genetic complexity, 1q21-q44 gains, 2p16/REL gains/amplifications, 19p13/CD70 homozygous deletions, and TP53 and MYC mutations. In conclusion, these findings further unravel the molecular heterogeneity of pediatric and young adult LBCL, improve the classification of this group of tumors, and provide new parameters for risk stratification.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Fatores Reguladores de Interferon / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Fatores Reguladores de Interferon / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha